Document Detail

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.
MedLine Citation:
PMID:  14975476     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study aimed to investigate the impact of hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) therapy in patients with advanced heart failure (HF). BACKGROUND: Although statins are known to reduce mortality in coronary artery disease (CAD), the impact of statin therapy in patients with HF has not been well studied. Both the potential risks and benefits of statins in HF have been described. METHODS: We studied a cohort of 551 patients with systolic HF (left ventricular ejection fraction [EF] <or=40%) referred to a single university center for clinical management and/or transplant evaluation. Survival without the necessity of urgent heart transplantation was determined. RESULTS: The patients' mean age was 52 +/- 13 years; mean EF was 25 +/- 7%. Forty-five percent of the cohort had CAD, and 45% were receiving statin therapy, including 73% and 22% of CAD and non-CAD patients with HF, respectively. Patients receiving statins were significantly older and more likely to be male, with higher rates of hypertension, diabetes, and smoking. The EF and cholesterol levels were similar between treated and non-treated patients. Statin use was associated with improved survival without the necessity of urgent transplantation in both non-ischemic and ischemic HF patients (91% vs. 72%, p < 0.001 and 81% vs. 63%, p < 0.001 at one-year follow-up, respectively). After risk adjustment for age, gender, CAD, cholesterol, diabetes, medications, hemoglobin, creatinine, and New York Heart Association functional class, statin therapy remained an independent predictor of improved survival (hazard ratio 0.41 95% confidence interval 0.18 to 0.94). CONCLUSIONS: Statin therapy is associated with improved survival in patients with ischemic and non-ischemic HF. Randomized trials are needed for confirmation of a therapeutic benefit.
Tamara B Horwich; W Robb MacLellan; Gregg C Fonarow
Related Documents :
11076126 - Post-hospitalization management of high-risk coronary patients.
15019536 - Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary a...
20215906 - Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary inte...
15788056 - Early initiation of statin therapy in acute coronary syndromes: a review of the evidence.
8772746 - The natural history of unheralded complex coronary plaques.
24850236 - Laronidase replacement therapy and left ventricular function in mucopolysaccharidosis i.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  43     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-02-20     Completed Date:  2004-03-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  642-8     Citation Subset:  AIM; IM    
Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California 90095-1679, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Follow-Up Studies
Heart Failure / drug therapy*,  etiology,  mortality*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Middle Aged
Survival Analysis
Time Factors
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission ...
Next Document:  Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of cor...